The results of the PDX model further verified the anti-tumor effect of targeting CDK16 in TNBC, which significantly delayed tumor occurrence (Fig. 3F), suppressed tumor growth (Fig. 3G), and finally inhibited tumor progression (Fig. 3H, I). The gene discussed is CDK16; the disease is neoplasm.